OTC non-prescription hearing aids are available to people in the US with perceived mild to moderate hearing loss. Since being made available nearly a year ago, OTC hearing aids have proven to increase uptake of hearing aids. The launch looks so promising, that current forecasting predicts a $1.7B market value for OTC hearing aids by 2030.
For providers of OTC hearing aids – including community healthcare providers and retailers – this market unlocks incredible opportunities to boost uptake of hearing care and revolutionize community-based hearing care. But with the benefits of OTC hearing aids also comes a unique set of challenges, and providers of such devices must acknowledge and address these in order to create the most positive health outcomes possible for the people who decide to use them.
AUDIMETROID is the world’s first purpose-built, accurate hearing testing technology for community-based healthcare providers. It’s a lightweight, scalable solution that’s designed to facilitate fast and easy adoption of hearing testing in communities. With AUDIMETROID, local healthcare providers and retailers are empowered to easily and quickly administer hearing tests that deliver immediate results with clinical levels of accuracy. Through on-the-spot testing, and by reducing the time between diagnosis of hearing loss and the provision of care, AUDIMETROID helps to drive adoption of OTC hearing aids, making it possible for community healthcare providers to offer more accessible, more comprehensive care to residents.
OTC non-prescription hearing aids are available to people in the US with perceived mild to moderate hearing loss. Since being made available nearly a year ago, OTC hearing aids have proven to increase uptake of hearing aids. The launch looks so promising, that current forecasting predicts a $1.7B market value for OTC hearing aids by 2030.
For providers of OTC hearing aids – including community healthcare providers and retailers – this market unlocks incredible opportunities to boost uptake of hearing care and revolutionize community-based hearing care. But with the benefits of OTC hearing aids also comes a unique set of challenges, and providers of such devices must acknowledge and address these in order to create the most positive health outcomes possible for the people who decide to use them.
AUDIMETROID is the world’s first purpose-built, accurate hearing testing technology for community-based healthcare providers. It’s a lightweight, scalable solution that’s designed to facilitate fast and easy adoption of hearing testing in communities. With AUDIMETROID, local healthcare providers and retailers are empowered to easily and quickly administer hearing tests that deliver immediate results with clinical levels of accuracy. Through on-the-spot testing, and by reducing the time between diagnosis of hearing loss and the provision of care, AUDIMETROID helps to drive adoption of OTC hearing aids, making it possible for community healthcare providers to offer more accessible, more comprehensive care to residents.
Drive patient-centric decision making and improve outcomes for users of OTC hearing aids
AUDIMETROID uses a spatial paradigm to test for hearing loss. During a test, a patient is asked to turn their head and body to face the perceived direction of sound. The paradigm is based on three-dimensional, physical distance, and produces incredibly reliable, accurate results that enable better, faster patient-centric decision making.
Hearing loss classification with AUDIMETROID
AUDIMETROID distinguishes between three categories of hearing or hearing loss: normal hearing, mild to moderate hearing loss, and severe (and more profound) hearing loss.
For those with normal hearing: AUDIMETROID will only yield a normal hearing test result if the patient/individual partaking in the test can prove that they consistently heard all of the test sounds. For this to occur, a patient must consistently localise the sound location of the test sounds. If a patient tries to guess where the sounds are coming from when they can’t actually hear them, it is highly unlikely that they will generate consistently correct results, which is where the AUDIMETROID spatial paradigm and analytical algorithms really show their strength: if a patient cannot hear the test sounds, the AUDIMETROID test will reveal as much. This means that patients who receive a normal hearing test result can rest assured that their hearing is, in fact, normal.
For those with mild to moderate hearing loss: AUDIMETROID quickly and accurately identifies individuals with mild to moderate hearing loss suitable for OTC hearing aids, enabling providers of such devices to offer on-the-spot fitting and drastically reduce the delay between diagnosis and the provision of care (a delay that increases the likelihood that a patient’s condition will worsen).
For those with severe hearing loss: Patients with severe and more profound hearing loss require forward referral to an audiologist. AUDIMETROID enables healthcare providers to identify these individuals quickly and accurately, averting the potential for misdiagnosis or misapplication of OTC hearing aids.
By arming healthcare providers with the most accurate and reliable data possible about an individual’s hearing loss, AUDIMETROID contributes to a testing and care experience that’s expedient, comfortable, and effective for patients and providers alike.
For more information about how AUDIMETROID can help your team drive better, faster, more patient-centric hearing care and treatment, just reach out to a member of the team.